Clinical efficacy and safety of anti-PD-1/PD-L1 treatments in non-small cell lung cancer (NSCLC).
Conclusion: Anti-PD-1/PD-L1 treatments show better clinical efficacy and higher safety than chemotherapy in NSCLC.
PMID: 31713435 [PubMed - in process]
Source: Artificial Cells, Nanomedicine and Biotechnology - Category: Biotechnology Tags: Artif Cells Nanomed Biotechnol Source Type: research
More News: Biotechnology | Cancer | Cancer & Oncology | Chemotherapy | Lung Cancer | Lung Transplant | Nanotechnology | Non-Small Cell Lung Cancer | Study